Eurofins Discovery supports COVID-19 research

By The Science Advisory Board staff writers

April 13, 2020 -- Eurofins Discovery has announced that it aims to accelerate COVID-19 antiviral drug discovery research.

Researchers are exploring treatment strategies for the disease that include targeting angiotensin-converting enzyme 2 (ACE2), transmembrane protease serine 2 (TMPRSS2), and the SARS-CoV-2 main protease, as well as large molecule therapies, the company said.

Eurofins Discovery offers these researchers the following services:

  • Bioassays and target specific assays
  • Custom assay development
  • Cytokine storm assessment
  • Drug repositioning services
  • Efficacy testing
  • Safety profiling

New antiviral drug could work against many viruses, including SARS-CoV-2
An antiviral drug called EIDD-2801 that's in preclinical testing has potential to be developed into the silver bullet that medical professionals seek...
Boehringer Ingelheim expands COVID-19 collaborations
Boehringer Ingelheim announced that it is significantly increasing support for the fight against COVID-19, particularly by adding a number of strategic...
Funding floodgates open for COVID-19 research
The impacts of the COVID-19 pandemic are being felt around the world. Researchers are working at a record-setting pace to understand the novel coronavirus...
CAS offers open-access chemical database for COVID-19
The Chemical Abstracts Service (CAS), a division of the American Chemical Society, announced it has released an open-access database of chemical compounds...
How AI is speeding development of COVID-19 therapies
As the world is facing a new challenge in trying to both adapt to and defend itself against the novel coronavirus, artificial intelligence (AI) is offering...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter